Abstract Number: 3175 • 2015 ACR/ARHP Annual Meeting
Strength at the Lumbar Spine and Hip Improves with Romosozumab Compared with Teriparatide in Postmenopausal Women with Low Bone Mass
Background/Purpose: Romosozumab is a bone-forming agent that inhibits sclerostin. In a phase 2 study (NCT00896532), 12 months of romosozumab increased DXA bone mineral density (BMD)…